A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Phase of Trial: Phase II
Latest Information Update: 14 Nov 2018
At a glance
- Drugs Ilodecakin (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms Cypress 2
- Sponsors ARMO Biosciences
- 01 Nov 2018 Planned End Date changed from 1 Dec 2021 to 25 Mar 2022.
- 01 Nov 2018 Planned primary completion date changed from 1 Jun 2019 to 27 Sep 2019.
- 31 Aug 2018 Biomarkers information updated